½ÃÀ庸°í¼­
»óǰÄÚµå
1728429

¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - Á¦Ç°º°, ¿ëµµº°, ÀûÀÀ Áúȯº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Point Of Care Lipid Test Market Size, Share & Trends Analysis Report By Product, By Application, By Disease Indication, By End-use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 80 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀåÀº 2030³â±îÁö 11¾ï ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£ µ¿¾È CAGR 6.5%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÉÇ÷°ü Áúȯ, ´ç´¢º´, ½ÅÀå Àå¾Ö¿Í °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀ̸ç, ÀÌ·¯ÇÑ Áúº´Àº Á¾Á¾ È¿°úÀûÀÎ °ü¸®¸¦ À§ÇØ ºó¹øÇÑ ÁöÁú ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÌ·¯ÇÑ µ¿ÇâÀº ÁöÁú ºÒ±ÕÇüÀÇ Á¶±â ¹ß°ßÀÌ Àå±âÀûÀÎ °Ç°­ À§ÇèÀ» ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ÁßÁ¡È­¿Í ÀÏÄ¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀ» µðÁöÅÐ Ç÷§Æû°ú ÅëÇÕÇÔÀ¸·Î½á À¯Çà½Ã¿¡ ±â¼¼¸¦ ´Ã¸° ¿ø°Ý ¸ð´ÏÅ͸µÀÌ °¡´ÉÇØÁ® ºÒÇÊ¿äÇÑ ÀÓ»ó ÁøÂûÀ» ÁÙÀ̱â À§ÇØ °è¼Ó À¯È¿ÇÕ´Ï´Ù.

POC ÁöÁú°Ë»ç ½ÃÀå º¸°í¼­ ¹× ÇÏÀ̶óÀÌÆ®

  • ¼Ò¸ðǰÀÌ Á¦Ç° ºÎ¹®À» Áö¹èÇÏ¿© 2024³â¿¡´Â 61.9%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • Àåºñ´Â ¿¹Ãø ±â°£ µ¿¾È CAGR 6.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • °íÁöÇ÷ÁõÀº 2024³â 46.9%ÀÇ ÃÖ´ë ÆÇ¸Å Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. À̰ÍÀº ÁÖ·Î ´ç´¢º´°ú ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ ½Å¼ÓÇϰí È¿°úÀûÀÎ °ü¸®ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â ¹è°æ¿¡ ÀÖ½À´Ï´Ù.
  • °íÆ®¸®±Û¸®¼¼¸®µåÇ÷ÁõÀº ¼Óµµ¿Í Á¢±Ù¼ºÀ» Çâ»ó½ÃŰ´Â °Ë»ç±â¼úÀÇ ±Þ¼ÓÇÑ °³¹ß·Î ¿¹Ãø±â°£ µ¿¾È CAGR 7.0%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
  • ÁöÁú ¹× ¸®Æ÷´Ü¹é Àå¾Ö°¡ ½ÃÀåÀ» ¼®±ÇÇØ 2024³âÀÇ ¼öÀÍ Á¡À¯À²Àº 38.7%·Î ÃÖ´ë¿´½À´Ï´Ù. ¾ÆÅ×·Ò¼º µ¿¸Æ°æÈ­ÁõÀº 2025³âºÎÅÍ 2030³â±îÁö ÇöÀúÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • º´¿ø ºÎ¹®Àº ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ ÁöÀ§¸¦ Â÷ÁöÇßÀ¸¸ç 2024³â¿¡´Â 32.2%·Î °¡Àå Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. º´¿øÀº ÀûÀýÇÑ Áø´Ü°ú ¸¸¼º »óÅÂÀÇ °ü¸®¸¦ °¡´ÉÇÏ°Ô Çϰí ȯÀÚÀÇ °á°ú¸¦ Çâ»ó½Ã۱â À§ÇØ ½Å¼ÓÇϰí Á¤È®ÇÑ ÁöÁú °Ë»ç°¡ ÇÊ¿äÇÕ´Ï´Ù.
  • ºÏ¹Ì´Â ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀåÀ» µ¶Á¡Çϰí 2024³â 43.6%ÀÇ ÃÖ´ë ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ÁÖ·Î ¿äÁ¡ °ü¸®¸¦ ¿ø°Ý ÀÇ·á Ç÷§Æû¿¡ ÅëÇÕÇÏ¿© »ç¿ë ÆíÀǼº°ú ȯÀÚ Âü¿©µµ¸¦ ³ôÀ̱⠶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®

Á¦4Àå ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå : Á¦Ç° ºñÁî´Ï½º ºÐ¼®

  • Á¦Ç° ºÎ¹® ´ë½Ãº¸µå
  • POC ÁöÁú°Ë»ç ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(Á¦Ç°º°, 2018-2030³â)
  • ±â±â
  • ¼Ò¸ðǰ

Á¦5Àå ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå : ¿ëµµº° ºñÁî´Ï½º ºÐ¼®

  • ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • POC ÁöÁú°Ë»ç ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(¿ëµµº°, 2018-2030³â)
  • °íÁöÇ÷Áõ
  • °íÆ®¸®±Û¸®¼¼¸®µåÇ÷Áõ
  • źÁö¿¡¸£º´
  • °í¸®Æ÷´Ü¹éÇ÷Áõ
  • °¡Á·¼º °íÄÝ·¹½ºÅ×·ÑÇ÷Áõ
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå : ÀûÀÀ Áúȯº° ºñÁî´Ï½º ºÐ¼®

  • ÀûÀÀ Áúȯ ºÎ¹® ´ë½Ãº¸µå
  • POC ÁöÁú°Ë»ç ½ÃÀå : ÀûÀÀ Áúȯ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(ÀûÀÀ Áúȯº°, 2018-2030³â)
  • ÁöÁú ¹× Áö´Ü¹éÁú Áúȯ
  • µ¿¸Æ°æÈ­Áõ
  • °£ ¹× ½ÅÀåÀÇ Áúº´
  • ´ç´¢º´
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ºñÁî´Ï½º ºÐ¼®

  • ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • POC ÁöÁú°Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®(ÃÖÁ¾ ¿ëµµº°, 2018-2030³â)
  • º´¿ø
  • Ŭ¸®´Ð
  • Á¶»ç ¹× Áø´Ü ½ÇÇè½Ç
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2030³â
  • Áö¿ªº° ¼¼°èÀÇ POC ÁöÁú°Ë»ç ½ÃÀå :ÁÖ¿ä Æ÷ÀÎÆ®
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷/°æÀïÀÇ ºÐ·ù
  • º¥´õ »óȲ
    • Key Company Heat Map Analysis, 2024
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Callegari
    • Abbott Laboratories
    • MiCoBio
    • Nova Biomedical Corporation
    • VivaChek Biotech(Hangzhou) Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Menarini Group
    • SD Biosensor, Inc e
JHS 25.06.02

Point Of Care Lipid Test Market Growth & Trends:

The global point of care lipid test market is anticipated to reach USD 1.1 billion by 2030 and is anticipated to expand at a CAGR of 6.5% over the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic conditions like cardiovascular diseases, diabetes, and kidney disorders is a key driver contributing to the market growth, as these conditions often necessitate frequent lipid monitoring for effective management. Cardiovascular complications remain a major concern for patients with kidney disease, where factors such as elevated lipid levels and systemic inflammation increase risks.

Furthermore, this trend aligns with the broader emphasis on preventive healthcare, where early detection of lipid imbalances helps mitigate long-term health risks. Portable testing devices enable real-time results at clinics, hospitals, or homes, streamlining patient care and empowering individuals to manage their health proactively. The integration of these tools with digital platforms supports remote monitoring, a practice that gained momentum during the pandemic and remains relevant for reducing unnecessary clinical visits.

Point Of Care Lipid Test Market Report Highlights:

  • Consumables dominated the product segment and accounted for the largest revenue share of 61.9% in 2024. This is attributed to the need for disposable and single-use consumables for rapid, user-friendly testing procedures.
  • Instruments are expected to grow at a CAGR of 6.6% over the forecast period, owing to contemporary analyzers' improved accuracy, mobility, and connectivity features, which make them perfect for decentralized situations.
  • The hyperlipidemia held the largest revenue share of 46.9% in 2024, primarily driven by the rising necessity for quick, effective management of chronic diseases such as diabetes and cardiovascular disease.
  • Hypertriglyceridemia is expected to grow at a CAGR of 7.0% over the forecast period, owing to the rapid developments in testing technologies that improve speed and accessibility.
  • Lipid and lipoprotein disorders dominated the market, with the largest revenue share of 38.7% in 2024. Atherosclerosis is expected to grow at a significant CAGR from 2025 to 2030.
  • The hospitals segment held the dominant position in the market and accounted for the largest revenue share, 32.2%, in 2024. Hospitals need quick, precise lipid testing to allow appropriate diagnosis and management of chronic situations, enhancing patient outcomes.
  • North America dominated the global point-of-care lipid test market and accounted for the largest revenue share of 43.6% in 2024, primarily due to the incorporation of point-of-care testing with telehealth platforms, which improves user-friendliness and patient engagement.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Disease Indication
    • 1.2.4. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. Disease Indication Outlook
    • 2.2.4. End Use Outlook
    • 2.2.5. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Point of Care Lipid Test Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Global Point of Care Lipid Test Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Global Point of Care Lipid Test Market: Product Business Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Point of Care Lipid Test Market: Product Movement Analysis
  • 4.3. Global Point of Care Lipid Test Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Consumables
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Global Point of Care Lipid Test Market: Application Business Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Point of Care Lipid Test Market: Application Movement Analysis
  • 5.3. Global Point of Care Lipid Test Market Size & Trend Analysis, By Application, 2018 to 2030 (USD Million)
  • 5.4. Hyperlipidemia
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Hypertriglyceridemia
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Tangier Disease
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Hyperlipoproteinemia
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8. Familial Hypercholesterolemia
    • 5.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Global Point of Care Lipid Test Market: Disease Indication Business Analysis

  • 6.1. Disease Indication Segment Dashboard
  • 6.2. Point of Care Lipid Test Market: Disease Indication Movement Analysis
  • 6.3. Global Point of Care Lipid Test Market Size & Trend Analysis, By Disease Indication, 2018 to 2030 (USD Million)
  • 6.4. Lipid and Lipoprotein Disorders
    • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Atherosclerosis
    • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Liver and Renal Diseases
    • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Diabetes Mellitus
    • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Global Point of Care Lipid Test Market: End Use Business Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. Point of Care Lipid Test Market: End Use Movement Analysis
  • 7.3. Global Point of Care Lipid Test Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5. Clinics
    • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6. Research and Diagnostic Laboratories
    • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Global Point of Care Lipid Test Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Regional Market Share Analysis, 2024 & 2030
  • 8.3. Global Point of Care Lipid Test Market by Regional: Key Takeaways
  • 8.4. North America
    • 8.4.1. U.S.
      • 8.4.1.1. Key Country Dynamics
      • 8.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 8.4.1.3. Competitive Scenario
      • 8.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Canada
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Mexico
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Germany
      • 8.5.1.1. Key Country Dynamics
      • 8.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 8.5.1.3. Competitive Scenario
      • 8.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.3. France
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Italy
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.5. Spain
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Denmark
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 8.5.6.3. Competitive Scenario
      • 8.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework/ Reimbursement Structure
      • 8.5.7.3. Competitive Scenario
      • 8.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework/ Reimbursement Structure
      • 8.5.8.3. Competitive Scenario
      • 8.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key Country Dynamics
      • 8.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 8.6.1.3. Competitive Scenario
      • 8.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.3. India
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework/ Reimbursement Structure
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Australia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework/ Reimbursement Structure
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Thailand
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework/ Reimbursement Structure
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework/ Reimbursement Structure
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key Country Dynamics
      • 8.7.1.2. Regulatory Framework/ Reimbursement Structure
      • 8.7.1.3. Competitive Scenario
      • 8.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Argentina
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 8.7.2.3. Competitive Scenario
      • 8.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8. Middle East & Africa
    • 8.8.1. South Africa
      • 8.8.1.1. Key Country Dynamics
      • 8.8.1.2. Regulatory Framework/ Reimbursement Structure
      • 8.8.1.3. Competitive Scenario
      • 8.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework/ Reimbursement Structure
      • 8.8.2.3. Competitive Scenario
      • 8.8.2.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.8.3. UAE
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework/ Reimbursement Structure
      • 8.8.3.3. Competitive Scenario
      • 8.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.8.4. Kuwait
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework/ Reimbursement Structure
      • 8.8.4.3. Competitive Scenario
      • 8.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key Company Heat Map Analysis, 2024
  • 9.4. Company Profiles
    • 9.4.1. Callegari
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Abbott Laboratories
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. MiCoBio
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Nova Biomedical Corporation
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. VivaChek Biotech (Hangzhou) Co., Ltd.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. F. Hoffmann-La Roche Ltd.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Menarini Group
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. SD Biosensor, Inc e
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦